ONCOINVENT Aktie

 

An extraordinary general meeting in Oncoinvent ASA will be held on 4. August 2025 at  12:00 CEST. The meeting will be held in Gullhaugveien 7, Oslo with the possibility for a virtual participation. The formal call will be sent to all shareholders registered in the Norwegian Central Security Depository (VPS). The complete set of documents and link relating to the extraordinary general meeting will be made available on www.oncoinvent.com/investors/general-meetings. Shareholders are recommended to exercise their shareholder rights through completing the proxy form with voting instruction....

OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the......

Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately NOK 130 million, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a...

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June 18, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company......

OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English on Wednesday 30th of April at 11.00 AM CEST. A webcast will be available for everyone to view......

OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with......

Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer, announces its fourth quarter 2024 results today. Webcast scheduled for February 27[th], 2025 at 10:00 CET. Link to webcast (https://teams.microsoft.com/l/meetup-join/19%3ameeting_YzM0N2I2MTktMDNhYy00YTQ0LWJkNzEtNjYxZTg2NDYwMTgy%40thread.v2/0?context=%7b%22Tid%22%3a%226da5bf1f-bdf4-4dbb-9493-01c5dcdde30e%22%2c%22Oid%22%3a%22284a9771-4a5d-4dd9-b18a-a6d449c818d0%22%7d) Highlights · Reported preliminary promising signal of efficacy and benign safety...

Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer. Radspherin® is a novel alpha-radiation therapy designed for targeted, direct treatment of cancers that have spread to body cavities. The Phase 2 is a randomised, open label, multicentre trial (NCT06504147) assessing the efficacy and safety of Radspherin® in patients with...